Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

Summary

Cediranib is being tested to assess its effectiveness on the growth of kidney cancer tumours and also how well it is tolerated.

Timeline

Start

2007-01

Primary completion

2008-03

Completion

2016-10

Outcome

Met primary endpoint

paper The primary study outcome revealed that, after 12weeks of therapy, there was a significant difference PMID 22285180 ↗

paper between the cediranib (-20%) and placebo (+20%) arms (p<0.0001). PMID 22285180 ↗

Publications

• Mulders P, Hawkins R, Nathan P, de Jong I, Osanto S, Porfiri E, Protheroe A, van Herpen CM, Mookerjee B, Pike L, Jurgensmeier JM, Gore ME. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. Eur J Cancer. 2012 Mar;48(4):527-37. doi: 10.1016/j.ejca.2011.12.022. Epub 2012 Jan 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cediranib	Small molecule	45 mg	Oral

Indications